For instance, identifying CSF flow abnormalities in genetically defined syndromes of ASD—and then conducting mechanistic experiments in the animal models of such syndromes (e.g., Fragile X, Tuberous Sclerosis, Dup15q, Angelman syndrome)—would help the field take the next step toward teasing apart biology and developing targeted treatments. This evidence concerns the gene GREM1 and Angelman syndrome.